Advertisements

Фексофенадин

Quick links to important sections

Фексофенадин

Advertisements
Advertisements

Treatment option: Hives, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Фексофенадин

What is Фексофенадин (Fexofenadine)?

Fexofenadine is the International Nonproprietary Name (INN) for a widely used medication that provides relief from allergic symptoms. It is a modern, second-generation antihistamine available globally under various brand names, such as Allegra and Telfast, and is often dispensed as an over-the-counter (OTC) medicine.

Quick Facts Overview

Property Description
Active Ingredient Fexofenadine Hydrochloride
Pharmacological Class Second-Generation Antihistamine
Primary Uses Seasonal Allergic Rhinitis (Hay Fever) and Chronic Urticaria (Hives)
Key Feature Non-sedating (Does not typically cause drowsiness)

Clinical and Pharmacological Profile

Fexofenadine is medically classified as a selective H1 receptor antagonist. This mechanism of action involves blocking the effects of histamine, a natural substance the body releases during an allergic reaction, which is responsible for symptoms like itching, sneezing, and inflammation. By blocking the H1 receptors, Fexofenadine prevents these symptoms from developing.

Fexofenadine is characterized by a favorable safety profile. Unlike older first-generation antihistamines, Fexofenadine is structurally designed to be highly selective and minimally crosses the blood-brain barrier. This selectivity allows it to be non-sedating, providing effective symptom relief while minimizing the risk of drowsiness or impairment of cognitive function.

Its primary clinical uses are for managing the uncomfortable symptoms of seasonal allergic rhinitis (hay fever) and for reducing the itching and size of lesions associated with chronic idiopathic urticaria (hives).

Advertisements

What side effects are possible with Фексофенадин?

Possible Side Effects and Safety Information

Fexofenadine's safety profile is formally documented by regulatory authorities, classifying adverse reactions primarily by frequency and the body systems affected. The most frequently reported adverse reactions, derived from clinical trial data, are classified as common (occurring in ge 1/100 to <1/10 patients). These effects include headache, drowsiness, dizziness, and nausea. Fatigue is listed as uncommon (occurring in ge 1/1,000 to <1/100 patients).

Post-marketing surveillance has identified additional adverse events where the precise frequency is not known, grouped within System-Organ Classes such as Psychiatric Disorders (e.g., insomnia, nervousness, sleep disorders) and Cardiac Disorders (e.g., tachycardia and palpitations).

Serious Adverse Reactions and Restrictions

Official regulatory documentation identifies hypersensitivity reactions as a rare but serious adverse event. These reactions, which include anaphylaxis, angioedema (swelling beneath the skin), chest tightness, and dyspnoea (difficulty breathing), are considered clinically significant and are listed in the Immune System Disorders class.

Fexofenadine is formally contraindicated in patients with known hypersensitivity to the active substance or any excipients. Furthermore, the regulatory safety profile notes that co-administration with aluminum and magnesium-containing antacids may reduce the absorption of fexofenadine, limiting its intended action. Certain fruit juices can also interfere with absorption.

Population-Specific Safety Notes

The prescribing information notes that fexofenadine exposure is increased in specific populations. This includes older adults and individuals with renal impairment, a factor accounted for in official safety considerations for these patient groups.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Reports of Fexofenadine overdose are documented as infrequent and contain limited specific information. The most commonly reported clinical manifestations are central nervous system (CNS) effects including dizziness and drowsiness (somnolence), along with dry mouth.

Regulatory documents advise caution for renally impaired patients because the drug's elimination half-life may be prolonged in this population, which is a key consideration in overdose management.

Emergency Response Statements

In the event of a suspected or actual overdose, official regulatory guidance mandates that individuals seek immediate emergency medical attention or call the Poison Help line immediately. Urgent assistance is required if severe clinical manifestations occur, such as collapse, seizure, difficulty breathing, or unconsciousness.

Overdose Context and Management

Management must focus on symptomatic and supportive treatment, employing standard measures to remove any unabsorbed drug. Regulatory data confirms that no specific antidote is known, and hemodialysis is not effective for the removal of fexofenadine hydrochloride from the blood. The official overdose profile is defined by these documented clinical manifestations and the clear, mandated need for professional emergency care.

Advertisements

Therapeutic Uses of Фексофенадин

Фексофенадин (fexofenadine) is a second-generation antihistamine that may be part of symptomatic management across conditions presenting with acute episodes where symptoms are linked to organ-specific functional stress due to an allergic response. This medication is primarily applied in addressing the symptoms of two main areas: seasonal allergic rhinitis (hay fever) and urticaria (hives)—conditions involving episodic or fluctuating manifestations.

Fexofenadine assists with day-to-day comfort during symptomatic periods by easing symptom clusters that may become intense or disruptive. This is commonly used when short-term symptomatic assistance is needed to relieve symptoms related to physical discomfort such as sneezing, a runny nose, an itchy throat, and red, itchy, or watery eyes. The medication is also relevant for easing symptoms associated with hives, including itching, swelling, and the appearance of red, raised skin areas, which often create noticeable physiological strain. This supportive relief may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“This supportive relief helps patients cope more steadily with symptom fluctuations during difficult episodes.”

Quick Fact: Relief for symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Fexofenadine eligibility is determined by specific population characteristics and medical history as defined in regulatory documents. The medication is absolutely contraindicated for patients with a known hypersensitivity to fexofenadine hydrochloride or any of the formulation's inactive ingredients.

Use is generally established for adults and adolescents (12 years and older) in standard tablet form. Specific lower age limits apply to children, with eligibility extending to children 6 months to 11 years for certain formulations and indications. Use in infants younger than six months is not established.

The medication is not recommended for use in pregnant women or breastfeeding women, as insufficient data exists for these groups and the drug is excreted into human milk. Conditional use or caution is required for several populations. This includes patients with impaired renal function due to documented changes in drug exposure, and older patients due to the higher likelihood of decreased kidney function. Caution is also advised for patients with pre-existing cardiovascular disease because of reported cardiac events associated with the antihistamine class. These eligibility rules strictly define who is permitted to use the medicine under regulatory guidance.

Advertisements

What should I know about interactions with other medicines?

Fexofenadine’s officially documented interaction profile is defined primarily by drug transporter interference and physical absorption constraints.

Medicinal Product Interactions

Co-administration with the P-glycoprotein (P-gp) inhibitors Erythromycin and Ketoconazole is officially documented to increase the systemic exposure (AUC and C max) of Fexofenadine. This clinically significant pharmacokinetic interaction requires specific caution due to reduced drug clearance.

Food and Timing Constraints

Aluminum and Magnesium Hydroxide Antacids significantly reduce the absorption of Fexofenadine. Regulatory documents state that these antacid products must not be taken within 2 hours of Fexofenadine to prevent decreased drug exposure. Similarly, consumption of fruit juices like grapefruit, apple, and orange significantly decreases bioavailability by inhibiting uptake transporters, necessitating their avoidance.

Pharmacodynamic and Population Notes

While Fexofenadine does not appear to potentiate the effects of alcohol, an official caution exists for additive pharmacodynamic effects with other Central Nervous System (CNS) depressants, which increases the documented risk of sedation. Furthermore, official labeling notes a population-specific consideration: patients with renal impairment may experience slower drug clearance, leading to the potential for increased systemic exposure.

Advertisements

Mechanism of Action

Фексофенадин (Fexofenadine) works by engaging specific molecular targets to modulate the activity of pathways associated with mediator release.


Selective Histamine H1 Receptor Antagonism

This mechanistic domain centers on fexofenadine's primary action as a selective peripheral H1 receptor inverse agonist/antagonist. It prevents the binding and subsequent signal transduction of histamine at the H1 receptor, a key step in cellular activation. By blocking this initial molecular step in the signaling cascade, the drug decreases the influence of heightened mediator concentrations, which reduces the magnitude of peripheral cellular responses.


Modulating Inflammatory Mediator Cascades

Fexofenadine engages mechanisms that regulate downstream cellular signaling beyond H1 receptor blockade. It has been shown to influence the production or release of various pro-inflammatory mediators, such as certain leukotrienes ( LTC4, LTD4) and prostaglandins. This modification of early molecular steps and subsequent signaling sequences results in reduced activation within targeted pathways, resulting in modified physiological consequences.

Advertisements

Dosage and Administration Information

Fexofenadine is administered via the oral route using available formulations such as tablets, oral suspension, and orally disintegrating tablets (ODT). The medication is generally used daily for the duration of symptomatic periods, with the frequency pattern being either once daily (QD) or twice daily (BID), as specified by the regulatory documents.

The standard labeled regimen for adults and children aged 12 years and older typically consists of 180 mg once daily or 60 mg twice daily. For children aged 6 to 11 years, the labeled dose is 30 mg twice daily. Specific instructions govern the timing of tablet intake, often directing administration before a meal in some regulatory areas.

Proper administration requires adherence to several mandatory procedural restrictions. Fexofenadine must be consumed with water only, as co-administration with fruit juices (including grapefruit, apple, or orange) is prohibited due to interference with absorption. Furthermore, to avoid significantly reduced systemic exposure, the administration must be separated from antacids containing aluminum and magnesium hydroxide by at least 2 hours.

A specific dosing adjustment is mandated for certain populations. For patients with decreased renal function (kidney impairment), the official labeling recommends a reduced dose, such as 60 mg once daily for adults and children 12 years and older, reflecting a population-specific standard in the usage protocol. Liquid forms, such as the oral suspension, require the bottle to be shaken well before each measurement using an accurate dosing device.

Advertisements

Recent Clinical Evidence

Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

Research has been conducted in the context of seasonal allergic rhinitis, often called hay fever, utilizing Randomized Controlled Trials (RCTs). These short-term studies, which compare Fexofenadine against a placebo, are aggregated into Systematic Reviews and meta-analyses to provide a broader view of the findings. The core study populations were typically Adults and Adolescents (age 12 and older). Studies monitored patient-reported outcomes describing perceived discomfort related to episodic or acute changes in symptoms, examining measures such as the Total Symptom Score (TSS) and outcomes reflecting daily functioning. Findings describe patterns observed in the studies where differences in measured outcomes were reported between the groups receiving the study product and those receiving the placebo. The follow-up durations for these key clinical studies were often limited (14 to 15 days). The evidence landscape relates to research conducted under specific conditions and populations, and some reviews note that certain earlier trials were assigned a medium risk of bias due to methodological limitations.


Evidence for Use in Chronic Urticaria (Hives)

For Chronic Urticaria (hives lasting six weeks or more), Fexofenadine was evaluated in a research context involving fluctuating or unstable symptoms. The evidence base includes Randomized Controlled Trials (RCTs) that often covered intermediate observation periods (four to six weeks). These studies explored the change in outcomes between standard amounts compared to escalated (higher-than-standard) amounts. The studies monitored outcomes linked to inflammatory or irritative states, focusing primarily on the severity of pruritus (itching), the number of wheals, and patient-reported discomfort that interfered with sleep and daily activities. Research focusing on episodes where symptoms become more noticeable and are not controlled by standard initial therapy is associated with known research limitations. Studies exploring the outcomes of escalating the dose reported mixed findings, and certainty remains low regarding the findings of higher-than-standard amounts.


Long-Term Studies and Follow-Up Data

The majority of the highest-quality evidence base, such as RCTs, is relevant in trials assessing short-term or episodic symptom patterns and typically does not extend beyond a few weeks or months. Follow-up durations were limited in the primary controlled trials for both hay fever and hives. Data for long-term outcomes are not fully established through controlled trials. Research observing responses over defined time intervals beyond six months is generally less extensive, and long-term patterns related to symptoms or recurrence are not well characterized by the existing controlled evidence.


Evidence in Special Populations

Fexofenadine was studied for use in several populations beyond the typical adult group, including Children (aged 6 months or older for chronic hives) and Adolescents. Research examined specific patterns and observed outcomes in these groups. The available data describes patterns related to how children reported their experience; however, data for certain groups remain insufficient. Studies also explored its use in patients with co-morbid allergic conditions, such as allergic conjunctivitis or asthma.


What Is Still Uncertain About Фексофенадин

A key limitation is that long-term outcomes are not fully established through controlled trials, particularly regarding continuous use over many months or years. Furthermore, comparative evidence is lacking in some areas; research has explored comparisons to other antihistamines, but the findings on comparative outcomes are not established across all available literature. Findings were mixed when evaluating the use of escalated doses for chronic urticaria, and evidence quality varies across studies for this specific clinical context.

Key Studies & References

  1. Fexofenadine: Pediatric drug information (NIH/MedlinePlus)
  2. Fexofenadine Overview (NIH/NCBI Bookshelf)
  3. Effect of dose escalation of second-generation antihistamines in the treatment of chronic spontaneous urticaria: a systematic review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Фексофенадин (FAQ)


Q: Does Фексофенадин start working right away or does it take a while?

Studies included in regulatory reviews have reported that antihistamine effects can begin as soon as one hour after a single dose. The maximum effect, which relates to the greatest reduction in symptoms, is generally described as occurring within two to three hours after consumption in studies.


Q: How long does the effect of a dose of Фексофенадин usually last?

The length of time the medication works is related to the dose strength that is used. Official documents indicate that an antihistamine effect is maintained for a duration that typically ranges from 12 to 24 hours, which aligns with the drug's use in clinical practice.


Q: Can taking Фексофенадин cause nervousness or anxiety?

Official post-marketing surveillance reports list nervousness and sleep disorders as adverse reactions, although the precise frequency of these events is not known. Some product information also lists anxiety as a less common side effect.


Q: Can Фексофенадин affect your sleep patterns?

Regulatory safety information lists certain sleep disorders and insomnia among the possible adverse reactions identified through post-marketing reports. These events are classified under the category of psychiatric disorders, but their exact frequency is uncertain.


Q: What is the general advice for using Фексофенадин during pregnancy?

Official labeling generally states that the medication is not recommended for use by pregnant women because insufficient data exists to fully establish safety for this group. It is generally stated that other allergy medications may have more complete safety data available.


Q: Can Фексофенадин be taken long-term for chronic conditions?

Most controlled trials supporting the use of Fexofenadine focused on short-term or episodic symptom control. However, research has generally indicated that tolerance to the drug’s effects has not been observed with longer periods of use, such as one month.


Q: What is the general information about using Фексофенадин while breastfeeding?

Official documents state that the drug is excreted into human milk, and therefore, use is generally not recommended for women who are breastfeeding due to a lack of sufficient data. However, government-supported resources suggest that adverse effects in breastfed infants would be unlikely.


Q: Is there a maximum time recommended for taking Фексофенадин continuously?

While the primary clinical studies were limited to assessing short-term use, official regulatory documentation does not specify a maximum time limit for continuous use. It is widely noted that the most extensive evidence relates to short-term symptom relief.


Q: What does official data say about the risk of severe side effects with Фексофенадин?

Regulatory documentation lists hypersensitivity reactions (including anaphylaxis, angioedema, and difficulty breathing) as serious adverse events. These are listed as clinically significant events in official documentation, though they are reported with unknown or rare frequency.


Q: Can Фексофенадин be taken with cold and flu medicine?

Official guidance suggests avoiding combination with other antihistamine products to help reduce the risk of increased side effects. However, Fexofenadine is often available in combined formulations with non-antihistamine products such as Pseudoephedrine.


Q: What if I forget a dose of Фексофенадин?

Patient information describes procedural steps that recommend taking the missed dose upon remembering, unless it is close to the next scheduled time. In that case, the guidance is that the missed dose may be disregarded and the regular schedule resumed.


Q: What is the risk of dependence or addiction with Фексофенадин?

Safety reviews related to the medication's non-prescription status have generally indicated a low risk regarding dependence or abuse potential. This assessment relates to the drug's properties as a modern, second-generation antihistamine.


Q: Is Фексофенадин available over the counter?

Yes, Fexofenadine is widely available in many countries as an Over-The-Counter (OTC) medicine, also known as a non-prescription product, in certain available strengths.


Q: What is the difference between different strengths of Фексофенадин?

The different available strengths are typically associated with differences in the frequency of dosing and the specific indications as described in the official regulatory labeling. For example, a 180 mg dose is often labeled for once-daily use, while a 60 mg dose is labeled for twice-daily use.


Q: Has there been research on how Фексофенадин affects driving ability?

Yes, official documents and specific studies have examined the effects on driving and psychomotor performance. These studies often indicate that the drug is unlikely to impair driving ability when used according to regulatory guidelines, which aligns with its classification as non-sedating.


Q: What are the signs of a possible allergic reaction to Фексофенадин?

Signs listed in patient safety documents that require prompt medical attention include rash or hives, swelling of the face or throat, chest tightness or trouble breathing, and very severe dizziness. These are noted as signs of possible serious hypersensitivity reactions.


Q: Is it normal to feel a bit dizzy after taking Фексофенадин?

Regulatory safety documentation lists dizziness as a common adverse reaction associated with Fexofenadine. A common reaction means it is reported to occur in a defined proportion of patients, making it a known and expected possibility when taking the medicine.


Q: Can Фексофенадин help with indoor dust mite allergies?

Fexofenadine is officially indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis, or hay fever. While dust mites are a known trigger for allergies, official regulatory indications focus on the overall allergic condition rather than listing specific allergens.


Q: What does the term 'selective peripheral H1-receptor antagonist' mean in simple terms?

In simple terms, this mechanism means the medication works by blocking the effects of histamine, the substance your body releases during an allergic reaction. The term 'peripheral' refers to the fact that it primarily works outside the brain, which is the reason for its non-sedating classification.


Q: Are there any warnings about using Фексофенадин before surgery?

Official documents do not provide general pre-operative warnings for this drug. However, caution is advised for patients with certain cardiovascular conditions. Regulatory guidance indicates that general medication use prior to a procedure is typically subject to discussion with a healthcare provider.


Q: Does Фексофенадин interact with herbal supplements?

Regulatory guidance advises informing a healthcare professional about all supplements being taken, including herbal remedies. Some published literature suggests that certain herbal supplements may interfere with the drug's absorption in the body.


Q: Are there any specific safety warnings for people with heart conditions using Фексофенадин?

Caution is advised for individuals with a history of pre-existing cardiovascular disease. Post-marketing reports specifically mention the risk of tachycardia (fast heart rate) and palpitations, which are effects associated with the antihistamine class.


Q: Does taking Фексофенадин prevent allergic reactions from starting?

The medication works by blocking the H1 receptors, which prevents histamine from binding to them and initiating the typical allergic response. This action stops the subsequent symptoms, such as sneezing and itching, from developing.


Q: Does Фексофенадин affect blood pressure?

Adverse event reporting for Fexofenadine alone does not typically list blood pressure changes as a frequently reported effect. However, product information for combination drugs that include Fexofenadine often advises caution for patients with high blood pressure.


Q: Is it true that Фексофенадин is less likely to cause dry mouth than some older allergy medicines?

Official regulatory documents do not list dry mouth (xerostomia) as a frequently reported side effect for Fexofenadine. This is because it is classified as a second-generation antihistamine, a class of medicine known to have less affinity for the receptors associated with anticholinergic effects like dry mouth.


Q: Is Фексофенадин effective for all types of nasal congestion?

Fexofenadine is specifically indicated for relieving nasal symptoms associated with Seasonal Allergic Rhinitis (hay fever). Official documents do not state its effectiveness for nasal congestion resulting from non-allergic causes, such as structural issues or the common cold.


Q: Why is the official guidance for Фексофенадин different in different countries?

Guidance on the use and availability of the drug may vary between countries due to differences in national regulatory procedures. These variations reflect each country's specific data review timing, local population safety considerations, and approval status.


Q: What research is available regarding the effects of long-term use of Фексофенадин?

The highest-quality evidence supporting the drug's primary indications is based on short-term controlled trials. However, dedicated long-term open-label studies have been conducted and reviewed to gather data on the safety profile of the drug over extended periods of continuous use.


Q: Can Фексофенадин be used to help symptoms of a common cold?

Official documents state that the medication is not indicated for the treatment of non-allergic symptoms, such as those caused by a common cold. Its primary indications are for allergic rhinitis and chronic urticaria.

Advertisements

How should Фексофенадин be stored and disposed of?

How to Store and Dispose of Fexofenadine

Fexofenadine tablets must be stored according to regulatory requirements to ensure stability. Official labeling specifies storage at Controlled Room Temperature (CRT), typically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and excessive heat, and should be kept in its original, tightly closed container.

Required Storage and Disposal Rules

  • Child Safety: Store the product out of the sight and reach of children.
  • Environmental Protection: Unused or expired medication must not be disposed of via wastewater or household waste.
  • Procedure: Consult a pharmacist or local waste disposal company for official instructions on how to discard the expired medicine properly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фексофенадин found in:

A-Z Index: